Mena (ENAH) Promotes KRAS-Driven Tumor Growth and Metastatic Progression in Pancreatic Ductal Adenocarcinoma

Ariyan, L. A.; Zambalde, E.; Li, J.; McAuliffe, T. T.; Ma, E.; Martinez, F. P.; Panarelli, N. C.; Eddy, R. J.; Patil, P.; Condeelis, J.; Gil-Henn, H.; McAuliffe, J. C.

doi:10.64898/2026.01.07.698161

bioRxiv · 10.64898/2026.01.07.698161

Mena (ENAH) Promotes KRAS-Driven Tumor Growth and Metastatic Progression in Pancreatic Ductal Adenocarcinoma

Ariyan, L. A.·Zambalde, E.·Li, J.·McAuliffe, T. T.·Ma, E.·Martinez, F. P.·Panarelli, N. C.·Eddy, R. J.·Patil, P.·Condeelis, J.·Gil-Henn, H.·McAuliffe, J. C.

View original source ↗Export metadata ↓

Abstract

Metastatic pancreatic ductal adenocarcinoma (PDAC) remains incurable and is projected to become the second leading cause of cancer-related death by 2030. Despite therapeutic advances, median survival remains under one year. Activating KRAS mutations drive the majority of PDAC and underlie their highly aggressive behavior. Although emerging KRAS inhibitors show promise, resistance limits their clinical efficacy, underscoring the need to identify additional regulators of mutant KRAS signaling. We investigated the role of the actin-regulatory protein Mena (ENAH) in KRASG12D-driven PDAC using novel in vitro and orthotopic in vivo models with Mena overexpression and knockdown. Mena overexpression markedly increased primary tumor growth and spontaneous liver metastasis, whereas Mena knockdown delayed tumor onset and reduced metastatic burden. Mechanistically, Mena depletion significantly decreased AKT and ERK activity downstream of KRAS in a SHIP2-mediated manner, indicating that Mena enhances oncogenic signaling required for PDAC progression. These findings reveal Mena as a critical modulator of KRASG12D-driven pancreatic tumor growth and metastasis. By promoting key survival and proliferation pathways, Mena contributes to the aggressive phenotype characteristic of KRAS-mutant PDAC and represents a promising therapeutic target for patients with both locoregional and metastatic disease.

Explore related subjects

cancer biology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Ariyan, L. A., Zambalde, E., Li, J., McAuliffe, T. T., Ma, E., Martinez, F. P., Panarelli, N. C., Eddy, R. J., Patil, P., Condeelis, J., Gil-Henn, H., McAuliffe, J. C.. 2026-01-08. Mena (ENAH) Promotes KRAS-Driven Tumor Growth and Metastatic Progression in Pancreatic Ductal Adenocarcinoma. https://doi.org/10.64898/2026.01.07.698161

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells

Pancreatic ductal adenocarcinoma (PDAC) progression involves malignant cell state plasticity. Epigenetic changes underlie this plasticity, yet the PDAC cis-regulatory landscape remains understudied. To address this, we profiled 33 primary tumors and 7 metastases from 39 patients with single-cell ATAC-seq, paired with 10 single-cell RNA-seq profiles. We found that epigenetic GATA6+/KRT17+ co-accessibility identifies a classical-basal subtype-intermediate progenitor state (SIP) associated with better clinical outcomes. SIP cells display limited epigenetic reprogramming from premalignant epithelium and retain gastric-intestinal differentiation reminiscent of neoplastic precursors. Lineages without GATA6+/KRT17+ co-accessibility exhibit greater lineage and epithelial-mesenchymal plasticity. Classical PDACs that repress basal gene accessibility activate neural-like progenitor (NRP) and tuft lineage enhancers, whereas basal committed tumors display esophageal transdifferentiation. Compared to SIP, classical-NRP and basal committed tumors have poorer outcomes, and show distinct PD-1/PD-L1 immune proteomic phenotypes and prognostic myofibroblast epigenetic states, respectively. Our work reveals links between lineage reprogramming, EMT, and epigenetic progression in human PDAC.

cancer biology↗

bioRxiv2026

Tissue resident CD4+ memory T-cells mark response to immune checkpoint inhibition in high-grade glioma

Background: Immune checkpoint inhibitors (ICI) are efficacious in many solid tumors, but response in glioma is restricted to a small subgroup. The determinants of response and resistance to ICI remain poorly understood. Methods: Here we exploit a syngeneic hypermutated high-grade glioma model with dichotomous response to combined PD-1 and CTLA-4 inhibition to unravel determinants of tumor-infiltrating T-cells driving response. Tumor-infiltrating T-cells from ICI-responsive and non-responsive tumors were analyzed by single-cell RNA and T-cell receptor sequencing and tumor-reactive T-cell receptor clonotypes were functionally validated to characterize their transcriptional phenotypes. We verify our findings in IDH1 wildtype glioblastoma patients treated with neoadjuvant pembrolizumab. Results: ICI response was associated with intratumoral clonal expansion of tumor-reactive cytotoxic T-cells and increased infiltration of CXCR6+ CD4+ tissue resident memory T-cells (Trm). CD4 stem-like memory T-cells in responding tumors demonstrated elevated interferon responses, following trajectories toward clonally expanded Trm, versus trajectories toward exhaustion in non-responsive tumors. In responsive tumors, CD4+ Trm interacted with infiltrating CXCR3+ tumor-reactive and clonally expanded, yet transcriptionally versatile cytotoxic T-cells. Probing the post neoadjuvant ICI high-grade glioma patient tissue dataset, we confirmed increased CXCR6 expression in CD4+ T cells and the association of CD4+ Trm with prolonged overall survival. Conclusion: These findings identify CD4 tissue-resident memory T-cells as determinants of ICI response in IDH1 wildtype high-grade glioma and warrant their further investigation to improve immunotherapy outcomes.

cancer biology↗

bioRxiv2026

Low-dose doxorubicin drives caveolin-1 depended re-epithelialization of breast cancer cells as a mechanism of cancer plasticity

Breast cancer progression is driven by dynamic changes in epithelial plasticity, membrane organization, and intracellular signaling, yet the effects of sustained low-dose chemotherapy on these processes remain poorly understood. Here, we investigated the impact of prolonged low-dose doxorubicin on membrane remodeling, epithelial phenotype, membrane-associated Ras lipid-anchor localization, and autophagy in mesenchymal-like MDA-MB-231 breast cancer cells. Low-dose doxorubicin significantly increased Caveolin-1 expression and enhanced E-cadherin protein levels, accompanied by a transition toward a more compact epithelial-like morphology with increased cell-cell contacts. Live-cell imaging demonstrated a significant reduction in the membrane-to-cytoplasm fluorescence ratio of the lipid-anchored GFP-tH probe, indicating redistribution from the plasma membrane to the cytoplasm following treatment. Analysis of autophagy-related proteins revealed decreased LC3-I together with increased LC3-II, ATG5, and p62 expression, consistent with autophagosome accumulation and impaired autophagic flux. Collectively, our findings demonstrate that low-dose doxorubicin promotes extensive remodeling of plasma membrane organization, epithelial plasticity, membrane-associated lipid-anchor localization, and autophagy. This integrated response reveals previously unrecognized links between membrane architecture, Ras membrane association, and autophagy during phenotypic reprogramming of breast cancer cells, providing mechanistic insight into cellular adaptations elicited by sub-cytotoxic doxorubicin exposure.

cancer biology↗